Skip to content

Seminar PH1 – “Wonder pills”, breakthroughs and continuing challenges – HIV and Hepatitis C antiviral treatments revisited

Room:

Hall G

Facilitator:

Stemer, Gunar

Speakers:

Abstract:


Linked to EAHP Statements:
Section 2: Selection, Procurement and Distribution
Section 4: Clinical Pharmacy Services

ACPE UAN:0475-0000-16-016-L04-P. A knowledge based activity.

Abstract

Thirty-five years ago in 1981 the American CDC (Centers for Disease Control) reported five cases of Pneumocystis pneumonia in five previously healthy young men and hypothesized about a cellular-immune dysfunction as the underlying cause. This report is now acknowledged as the first scientific report on what would become known as the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). Eight years later, in 1989, the discovery of the Hepatitis C virus shed light on the majority of, at that time unexplainable cases of non-A and non-B virus hepatitis. Since then, significant research efforts have been undertaken to better understand the two viruses and associated diseases, raise awareness, prevent transmission and develop effective antiviral treatments against HIV and Hepatitis C virus. Nevertheless, both diseases still represent a major public health burden with high prevalence of infected people and no decline of new HIV infections in Europe (European Centre for Disease Control 2014).

The accomplished achievements in medicines development led to a variety of antiviral treatments for HIV during the last three decades. Especially, the possibilities of Hepatitis C treatment have dramatically changed with the advent of new direct antiviral agents in the last 5 years. For hospital pharmacists it is crucial to keep track of new antiviral treatments and their effectiveness and safety in daily practice and to have state-of-the-art knowledge of HIV and Hepatitis C virus treatment guidelines.

Teaching goals:

• To illustrate the effectiveness/safety profiles of new treatment approaches;
• To provide a succinct update on current HIV and Hepatitis C treatment guidelines;
• To inform hospital pharmacists about treatment strategies in development that can be expected in the (near) future (e.g. medicines, vaccinations).
 
Learning objectives

After the seminar, the participants should be able:
• to outline the significance and impact of new medicines in the treatment of HIV and Hepatitis C virus;
• to provide examples of future treatments against HIV and Hepatitis C virus.
 
Keywords: HIV, Hepatitis, antiviral , immunodeficiency 
×

EAHP Forum

All the EAHP team is working on providing a Forum that can help connect all the members in Conversations and Groups to talk about important matters for the European Hospital Pharmacist.

The Forum will be accessible for all the EAHP members, you don’t have to create a new account to browse and participate.

Conversations and groups

The Conversations will be moderated by our team to provide documents and relevant topics for the community.

The Groups will connect all members that share a category. Members who work on the same assocation, on the same hospital, that have the same role, etc.

Stay tuned for the realase of the forum. Soon on EAHP.